Literature DB >> 9590173

Jak2 is essential for signaling through a variety of cytokine receptors.

E Parganas1, D Wang, D Stravopodis, D J Topham, J C Marine, S Teglund, E F Vanin, S Bodner, O R Colamonici, J M van Deursen, G Grosveld, J N Ihle.   

Abstract

A variety of cytokines activate receptor-associated members of the Janus family of protein tyrosine kinases (Jaks). To assess the role of Jak2, we have derived Jak2-deficient mice. The mutation causes an embryonic lethality due to the absence of definitive erythropoiesis. Fetal liver myeloid progenitors, although present based on the expression of lineage specific markers, fail to respond to erythropoietin, thrombopoietin, interleukin-3 (IL-3), or granulocyte/macrophage colony-stimulating factor. In contrast, the response to granulocyte specific colony-stimulating factor is unaffected. Jak2-deficient fibroblasts failed to respond to interferon gamma (IFNgamma), although the responses to IFNalpha/beta and IL-6 were unaffected. Lastly, reconstitution experiments demonstrate that Jak2 is not required for the generation of lymphoid progenitors, their amplification, or functional differentiation. Therefore, Jak2 plays a critical, nonredundant role in the function of a specific group of cytokines receptors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9590173     DOI: 10.1016/s0092-8674(00)81167-8

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  314 in total

1.  Jak3 selectively regulates Bax and Bcl-2 expression to promote T-cell development.

Authors:  R Wen; D Wang; C McKay; K D Bunting; J C Marine; E F Vanin; G P Zambetti; S J Korsmeyer; J N Ihle; J L Cleveland
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

2.  Regulation of the Jak2 tyrosine kinase by its pseudokinase domain.

Authors:  P Saharinen; K Takaluoma; O Silvennoinen
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

Review 3.  Jaks and stats as therapeutic targets.

Authors:  J J O'Shea; R Visconti; T P Cheng; M Gadina
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

4.  JAK2, complemented by a second signal from c-kit or flt-3, triggers extensive self-renewal of primary multipotential hemopoietic cells.

Authors:  Shengming Zhao; Karen Zoller; Masayoshi Masuko; Ponlapat Rojnuckarin; Xuexian O Yang; Evan Parganas; Kenneth Kaushansky; James N Ihle; Thalia Papayannopoulou; Dennis M Willerford; Tim Clackson; C Anthony Blau
Journal:  EMBO J       Date:  2002-05-01       Impact factor: 11.598

5.  Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1.

Authors:  Daniela Ungureanu; Pipsa Saharinen; Ilkka Junttila; Douglas J Hilton; Olli Silvennoinen
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

6.  Stat1-independent regulation of gene expression in response to IFN-gamma.

Authors:  C V Ramana; M P Gil; Y Han; R M Ransohoff; R D Schreiber; G R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

Review 7.  Series introduction. JAK-STAT signaling in human disease.

Authors:  Christian W Schindler
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

Review 8.  Role of the JAK/STAT signal transduction pathway in the regulation of gene expression in CNS.

Authors:  P Dell'Albani; R Santangelo; L Torrisi; V G Nicoletti; A M Giuffrida Stella
Journal:  Neurochem Res       Date:  2003-01       Impact factor: 3.996

9.  Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain.

Authors:  Pipsa Saharinen; Mauno Vihinen; Olli Silvennoinen
Journal:  Mol Biol Cell       Date:  2003-04       Impact factor: 4.138

10.  The SH2B1 adaptor protein associates with a proximal region of the erythropoietin receptor.

Authors:  Mojib Javadi; Edda Hofstätter; Natalie Stickle; Bryan K Beattie; Robert Jaster; Christin Carter-Su; Dwayne L Barber
Journal:  J Biol Chem       Date:  2012-06-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.